TY - JOUR T1 - One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. AU - Lin,Tzou-Yien, AU - Wang,Ying-Hsiang, AU - Huang,Yhu-Chering, AU - Chiu,Cheng-Hsun, AU - Lin,Pen-Yi, AU - Chen,Chih-Jung, AU - Chavand,Pascale, AU - Ortiz,Esteban, Y1 - 2007/03/08/ PY - 2006/06/28/received PY - 2006/12/15/revised PY - 2007/01/21/accepted PY - 2007/3/14/pubmed PY - 2008/1/11/medline PY - 2007/3/14/entrez SP - 488 EP - 95 JF - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases JO - Int J Infect Dis VL - 11 IS - 6 N2 - OBJECTIVE: To evaluate antibody persistence one year after three-dose primary vaccination and booster immune response during the second year of life for a fully liquid diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis-Haemophilus influenzae type b (DTaP-IPV-PRP approximately T) vaccine. METHODS: Infants at 18-19 months of age were given a booster dose of either DTaP-IPV-PRP approximately T (group A) or DTaP-IPV plus PRP approximately T at separate injection sites (group B), after primary vaccination at two, four and six months of age, with the same vaccines. Antibody concentrations were measured pre- and post-booster. Reactogenicity and safety were evaluated from parent reports. RESULTS: Before the booster dose, 93.1% of group A and 95.1% of group B children still had anti-PRP antibody titers > or =0.15 microg/ml. All children had antibody levels believed to protect against tetanus, polio 1 (except one subject in group B), polio 2, polio 3, and diphtheria (except one subject in group A). At least 94% of children still had antibody concentrations > or =5 ELISA units (EU) to pertussis antigens (pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), fimbriae 2 and 3 (FIM2+3)). One month after the booster dose, all subjects achieved antibody concentrations or titers believed to be protective for PRP (polyribose ribitol phosphate)(> or =1 microg/ml), diphtheria and tetanus (> or =0.1 IU/ml) and poliovirus types 1, 2, and 3 (> or =81/dil.), and at least 90.5% of subjects had four-fold increases in antibody concentrations to pertussis antigens following the booster. Anti-PRP geometric mean titers (GMTs) increased from 1.07 to 59.6 microg/ml and from 1.8 to 62.2 microg/ml in groups A and B, respectively. Both vaccine groups showed low reactogenicity rates. CONCLUSIONS: The fully liquid pentavalent DTaP-IPV-PRP approximately T vaccine is highly immunogenic, with good antibody persistence for each antigen approximately one year after primary vaccination and strong booster responses at 18-19 months of age. Because this combined vaccine is fully liquid, requiring no reconstitution of lyophilized PRP approximately T, the ease of use and proper administration are improved. SN - 1201-9712 UR - https://www.unboundmedicine.com/medline/citation/17349809/One_year_post_primary_antibody_persistence_and_booster_immune_response_to_a_fully_liquid_five_component_acellular_pertussis_diphtheria_tetanus_inactivated_poliomyelitis_Haemophilus_influenzae_type_b_conjugate_vaccine_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1201-9712(07)00030-6 DB - PRIME DP - Unbound Medicine ER -